Celularity Amends Senior EVP's Employment Agreement, Enhancing Severance and Accelerating Option Vesting
CELU sits 25% above its 52-week low of $1.001 on light trading volume (0.1× avg).
Summary
Celularity Inc. has amended the employment agreement for its Senior Executive Vice President, John Haines, significantly increasing his severance period and accelerating the vesting of equity options upon termination.
Key Events · Executive and Board Changes · CELU
-
Executive Employment Agreement Amended
Celularity Inc. approved the First Amendment to the employment agreement of John Haines, Senior Executive Vice President, Global Manager and Chief Administrative Officer.
-
Enhanced Severance Terms
The severance period for Mr. Haines was increased from 12 months to 24 months, and COBRA payment was extended to 18 months.
-
Accelerated Equity Vesting
Equity options that would have vested over a 24-month period after termination will now vest immediately upon termination.
Analysis · CELU · Life Sciences
The amendment to John Haines' employment agreement, a Senior Executive Vice President and Chief Administrative Officer, is notable for Celularity Inc., a micro-cap company. The changes, which include doubling the severance period to 24 months and immediately vesting 24 months of equity options upon termination, increase the company's potential financial obligations in the event of an executive departure. This could be interpreted as a 'golden parachute' provision, potentially impacting future shareholder value through increased costs or dilution.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELU was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $1.00 to $4.35. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.